Principal Financial Group Inc. Has $3.92 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Principal Financial Group Inc. grew its stake in shares of REGENXBIO Inc. (NASDAQ:RGNXFree Report) by 3.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 238,350 shares of the biotechnology company’s stock after acquiring an additional 7,977 shares during the period. Principal Financial Group Inc.’s holdings in REGENXBIO were worth $3,923,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Captrust Financial Advisors lifted its holdings in shares of REGENXBIO by 742.1% during the first quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 846 shares during the period. Royal Bank of Canada lifted its holdings in shares of REGENXBIO by 189.8% during the third quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 915 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in shares of REGENXBIO during the fourth quarter worth $38,000. PNC Financial Services Group Inc. lifted its holdings in shares of REGENXBIO by 103.6% during the second quarter. PNC Financial Services Group Inc. now owns 1,963 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 999 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of REGENXBIO during the second quarter worth $44,000. Institutional investors own 88.80% of the company’s stock.

REGENXBIO Trading Up 11.6 %

RGNX opened at $14.57 on Thursday. REGENXBIO Inc. has a 1-year low of $11.83 and a 1-year high of $25.32. The company has a market cap of $640.93 million, a P/E ratio of -2.44 and a beta of 1.20. The company has a fifty day moving average price of $16.59 and a two-hundred day moving average price of $17.10.

REGENXBIO (NASDAQ:RGNXGet Free Report) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($1.41) earnings per share for the quarter, beating the consensus estimate of ($1.44) by $0.03. REGENXBIO had a negative net margin of 262.18% and a negative return on equity of 59.54%. The firm had revenue of $28.90 million during the quarter, compared to the consensus estimate of $26.14 million. During the same period in the previous year, the firm posted ($1.75) earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year. On average, research analysts forecast that REGENXBIO Inc. will post -4.99 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on RGNX. Wedbush reiterated a “neutral” rating and set a $21.00 price target on shares of REGENXBIO in a report on Wednesday, January 17th. William Blair restated a “neutral” rating and issued a $21.00 target price (up previously from $20.00) on shares of REGENXBIO in a report on Tuesday, November 14th. Finally, Stifel Nicolaus began coverage on shares of REGENXBIO in a report on Wednesday, November 1st. They issued a “buy” rating and a $35.00 target price on the stock. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.71.

View Our Latest Research Report on REGENXBIO

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, insider Steve Pakola sold 17,237 shares of REGENXBIO stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.39, for a total value of $299,751.43. Following the completion of the sale, the insider now directly owns 107,192 shares of the company’s stock, valued at $1,864,068.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Steve Pakola sold 17,237 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $17.39, for a total transaction of $299,751.43. Following the completion of the sale, the insider now directly owns 107,192 shares of the company’s stock, valued at $1,864,068.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kenneth T. Mills sold 45,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $15.18, for a total transaction of $683,100.00. Following the sale, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at $6,193,971.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,237 shares of company stock valued at $1,868,451. Corporate insiders own 13.60% of the company’s stock.

About REGENXBIO

(Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

See Also

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNXFree Report).

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.